Income Statement (Annual)

LJPC / La Jolla Pharmaceutical Co. Income Statement shows changes in income and expenses over a period of time. Income Statement data includes Sales and Revenue, Gross Profit, Research and Development (R&D), Selling, General and Adminstrative Expense (SG&A), Operating Income, Income Tax Expense, Interest Expense, Non-Operating Income, Earnings per Share (EPS), and Shares Outstanding.

All numbers are times 1,000 except per share units.

2010 2011 2012 2013 2014 2015 2016 2017
Revenues
  Revenue From Contract With Customer Including Assessed Tax - - - - - - - -
  Revenues - - - 0 0 1,057 616 0
Costs And Expenses
  Cost Of Goods And Services Sold - - - - - - - -
  Research And Development Expense 13 177 1,353 4,362 9,944 29,092 62,288 84,575
  General And Administrative Expense 3,915 2,097 9,386 13,577 11,396 13,934 16,700 30,852
  Costs And Expenses 3,928 2,274 10,739 17,939 21,340 43,026 78,988 115,427
Operating Income Loss -3,928 -2,274 -10,739 -17,939 -21,340 -41,969 -78,372 -115,427
Interest Income Expense Net - - - - - - - -
Net Income Loss -3,760 -11,548 -7,737 -17,935 -21,313 -41,912 -78,185 -114,803
Earnings Per Share Basic And Diluted -0 -0 -0 -0 -0 -0 -0 -0
Weighted Average Number Of Share Outstanding Basic And Diluted - 369 10,196 454,337 10,667 15,651 17,228 21,215

Peers - Biological Products, Except Diagnostic Substances (Biotech) (2836)

Related News Stories

Stocks To Watch: Time To Talk Valuation

2018-09-01 seekingalpha
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. (298-8)

7 Biotech Stocks Insiders Are Loading Up On

2018-08-22 247wallst
Biotechnology stocks have a reputation for being some of the most speculative, most volatile stocks out there. Investors and would-be investors have to stay alert to avoid getting burned. One encouraging sign in any company is when insiders put their money where their mouth is and buy shares. Lately, some insiders at biotech companies have been doing just that, sometimes taking advantage of share price moves (not to mention buy windows opening up) in the wake of the release of quarterly reports. (24-12)

La Jolla Pharmaceutical Co (LJPC) CEO George Tidmarsh on Q2 2018 Results - Earnings Call Transcript

2018-08-09 seekingalpha
La Jolla Pharmaceutical Co (NASDAQ:LJPC) Q2 2018 Earnings Conference Call August 8, 2018 4:30 PM ET

Galectin Therapeutics IPF Patent Solidifies Platform Technology Status

2018-07-05 seekingalpha
Galectin Therapeutics (NASDAQ:GALT) announced on June 27th its patent for the method and treatment of Idiopathic Pulmonary Fibrosis (NYSEARCA:IPF). The significance of this patent was initially received as extremely positive by the market, but recent structural pressures like the option exercise of a key departing officer continued to weigh on the price. Based on the recent Form 4 Filings, the selling pressure has abated because the officers have simply run out of options to sell. (24-2)

2 Stable and 2 Speculative Biotech Stocks to Buy | InvestorPlace

2018-06-15 investorplace
Biotech stocks represent a peculiar conundrum. On one hand, they are scientifically the most exciting investment sector. Successes here could spark revolutionary therapies that could end or at least alleviate human suffering. But the industry is heavily marked with failures and agonizing disappointments. (7-1)

CUSIP: 503459604